Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 16/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790543 | 1.00 | NFE2L2 (0.51) | NFE2L2FLT3PIM1PABPC1RAB9A | |
| SCHEMBL5787790 | 0.82 | NFE2L2 (0.51) | NFE2L2FLT3PABPC1RAB9AEIF4H | |
| SCHEMBL5787784 | 0.82 | NFE2L2 (0.51) | NFE2L2FLT3PABPC1RAB9AEIF4H | |
| SCHEMBL8101251 | 0.81 | APP (0.46) | NFE2L2FLT3PIM1RAB9A | |
| SCHEMBL8101255 | 0.81 | APP (0.46) | NFE2L2FLT3PIM1RAB9A | |
| SCHEMBL5791782 | 0.81 | NFE2L2 (0.53) | NFE2L2FLT3RAB9A | |
| SCHEMBL5791786 | 0.81 | NFE2L2 (0.53) | NFE2L2FLT3RAB9A | |
| SCHEMBL5787278 | 0.79 | HRH4 (0.44) | — | |
| SCHEMBL5787273 | 0.79 | HRH4 (0.44) | — | |
| SCHEMBL5787731 | 0.78 | PTGS1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335906-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-6657060-B2 | Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia | HOFFMAN-LA ROCHE INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1335906-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2003-08-20 | — | — | EP | disclosed |
| US-20020086858-A1 | Pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | US | disclosed |
| WO-2002038551-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086858-A1 | Pyrimidine derivatives | NPY1R, NPY5R, NPY4R | NFE2L2 3894/4885FLT3 374/4885PIM1 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.